-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
introduction
introduction On September 8, the clinical application of the first domestic SIRPα monoclonal antibody IBI397 submitted by Innovent was accepted by the CDE
.
It is reported that IBI397 is a project introduced by Cinda Biotech and Alector, Inc.
in 2020 (R&D code AL008), and it has not entered the clinical stage at home and abroad
(Source: CDE official website)
IBI397 is an antibody that non-competitively inhibits SIRP-α/CD47 signaling.
It does not directly block the signaling pathway, but reduces the SIRP-α/CD47 pathway by inducing SIRP-α endocytosis and degradation on macrophages.
Signal to achieve the effect of lifting immunosuppression
CD47 -SIRPα pathway
CD47 -SIRPα pathway CD47 -SIRPα pathway CD47 -SIRPα pathway -SIRPα pathway SIRPα is the Signal Regulatory Protein Alpha, which is mainly expressed on the surface of myeloid hematopoietic cells such as macrophages, monocytes, dendritic cells and granulocytes
.
CD47 (Leukocyte surface antigen) is one of the ligands of SIRPα .
SIRPα CD47 One of the ligands of SIRPα , CD47 binds to SIRP α to prevent macrophages from phagocytosis of normal cells.
(Targeting the mechanism of CD47-SIRPα pathway in tumors Source: [3])
Cinda Bio
Cinda Bio Founded in 2011, Cinda Bio is committed to the development, production and sales of innovative drugs for the treatment of major diseases such as tumors
.
Cinda has deployed multiple high-potential targets in the oncology field, and has also made many major advances in non-tumor fields such as autoimmunity, metabolism and cardiovascular
5 commercial varieties money Dabo Shu ® up with ® Yau Su Lixin ® Dabo Hua ® Dabo Tan ® 6, paragraph 3.
(Tumor pipeline)
(Non-tumor pipeline)
Reference source:
Reference source: Reference source:[1] CDE official website
[1] CDE official website[2] Cinda Biological Semi-annual Report
[2] Cinda Biological Semi-annual Report[3] Mark P.
[3] Mark P.
[4] Murata Y, Saito Y, Kotani T, Matozaki T.
Blockade of CD47 or SIRPα: a new cancer immunotherapy.
Expert Opin Ther Targets.
2020.
